| Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV TP Sheahan, AC Sims, SR Leist, A Schäfer, J Won, AJ Brown, ... Nature communications 11 (1), 222, 2020 | 2137 | 2020 |
| Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses TP Sheahan, AC Sims, RL Graham, VD Menachery, LE Gralinski, ... Science translational medicine 9 (396), eaal3653, 2017 | 1827 | 2017 |
| Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease ML Agostini, EL Andres, AC Sims, RL Graham, TP Sheahan, X Lu, ... MBio 9 (2), 10.1128/mbio. 00221-18, 2018 | 1390 | 2018 |
| An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice TP Sheahan, AC Sims, S Zhou, RL Graham, AJ Pruijssers, ML Agostini, ... Science translational medicine 12 (541), eabb5883, 2020 | 1066 | 2020 |
| A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures KH Dinnon III, SR Leist, A Schäfer, CE Edwards, DR Martinez, ... Nature 586 (7830), 560-566, 2020 | 647 | 2020 |
| Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis LE Gralinski, TP Sheahan, TE Morrison, VD Menachery, K Jensen, ... MBio 9 (5), 10.1128/mbio. 01753-18, 2018 | 598 | 2018 |
| Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase AJ Brown, JJ Won, RL Graham, KH Dinnon III, AC Sims, JY Feng, T Cihlar, ... Antiviral research 169, 104541, 2019 | 559 | 2019 |
| A mouse-adapted SARS-CoV-2 induces acute lung injury and mortality in standard laboratory mice SR Leist, KH Dinnon, A Schäfer, VT Longping, K Okuda, YJ Hou, A West, ... Cell 183 (4), 1070-1085. e12, 2020 | 482 | 2020 |
| Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice AJ Pruijssers, AS George, A Schäfer, SR Leist, LE Gralinksi, KH Dinnon, ... Cell reports 32 (3), 2020 | 477 | 2020 |
| SARS-like WIV1-CoV poised for human emergence VD Menachery, BL Yount Jr, AC Sims, K Debbink, SS Agnihothram, ... Proceedings of the National Academy of Sciences 113 (11), 3048-3053, 2016 | 447 | 2016 |
| Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2 AC Walls, B Fiala, A Schäfer, S Wrenn, MN Pham, M Murphy, ... Cell 183 (5), 1367-1382. e17, 2020 | 445 | 2020 |
| Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants D Deming, T Sheahan, M Heise, B Yount, N Davis, A Sims, M Suthar, ... PLoS medicine 3 (12), e525, 2006 | 321 | 2006 |
| Synthetic recombinant bat SARS-like coronavirus is infectious in cultured cells and in mice MM Becker, RL Graham, EF Donaldson, B Rockx, AC Sims, T Sheahan, ... Proceedings of the National Academy of Sciences 105 (50), 19944-19949, 2008 | 317 | 2008 |
| Small-Molecule Antiviral β-d-N4-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance ML Agostini, AJ Pruijssers, JD Chappell, J Gribble, X Lu, EL Andres, ... Journal of virology 93 (24), 10.1128/jvi. 01348-19, 2019 | 310 | 2019 |
| Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo A Schäfer, F Muecksch, JCC Lorenzi, SR Leist, M Cipolla, S Bournazos, ... Journal of Experimental Medicine 218 (3), e20201993, 2020 | 303 | 2020 |
| A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus WA Fischer, JJ Eron Jr, W Holman, MS Cohen, L Fang, LJ Szewczyk, ... Science translational medicine 14 (628), eabl7430, 2021 | 284 | 2021 |
| β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells S Zhou, CS Hill, S Sarkar, LV Tse, BMD Woodburn, RF Schinazi, ... The Journal of infectious diseases 224 (3), 415-419, 2021 | 284 | 2021 |
| Genomic RNA elements drive phase separation of the SARS-CoV-2 nucleocapsid C Iserman, CA Roden, MA Boerneke, RSG Sealfon, GA McLaughlin, ... Molecular cell 80 (6), 1078-1091. e6, 2020 | 259 | 2020 |
| Modeling hepatitis C virus infection using human induced pluripotent stem cells RE Schwartz, K Trehan, L Andrus, TP Sheahan, A Ploss, SA Duncan, ... Proceedings of the National Academy of Sciences 109 (7), 2544-2548, 2012 | 253 | 2012 |
| Molnupiravir, an oral antiviral treatment for COVID-19 W Fischer, JJ Eron Jr, W Holman, MS Cohen, L Fang, LJ Szewczyk, ... MedRxiv, 2021.06. 17.21258639, 2021 | 226 | 2021 |
